OKYO Valuation
OKYO Pharma Ltd
$
2.700
OKYO Relative Valuation
OKYO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, OKYO is overvalued; if below, it's undervalued.
Historical Valuation
OKYO Pharma Ltd (OKYO) is now in the Fair zone, suggesting that its current forward PS ratio of 2.74 is considered Fairly compared with the five-year average of -5.35. The fair price of OKYO Pharma Ltd (OKYO) is between to according to relative valuation methord.
Relative Value
Fair Zone
-
Current Price：2.74
Fair
-14.81
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
OKYO Pharma Ltd. (OKYO) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -0.19. The thresholds are as follows: Strongly Undervalued below -10.21, Undervalued between -10.21 and -5.20, Fairly Valued between 4.82 and -5.20, Overvalued between 4.82 and 9.83, and Strongly Overvalued above 9.83. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-12.75
EV/EBIT
OKYO Pharma Ltd. (OKYO) has a current EV/EBIT of -12.75. The 5-year average EV/EBIT is -4.77. The thresholds are as follows: Strongly Undervalued below -11.65, Undervalued between -11.65 and -8.21, Fairly Valued between -1.33 and -8.21, Overvalued between -1.33 and 2.11, and Strongly Overvalued above 2.11. The current Forward EV/EBIT of -12.75 falls within the Strongly Undervalued range.
2.74
PS
OKYO Pharma Ltd. (OKYO) has a current PS of 2.74. The 5-year average PS is 0.02. The thresholds are as follows: Strongly Undervalued below -0.42, Undervalued between -0.42 and -0.20, Fairly Valued between 0.24 and -0.20, Overvalued between 0.24 and 0.46, and Strongly Overvalued above 0.46. The current Forward PS of 2.74 falls within the Strongly Overvalued range.
0.00
P/OCF
OKYO Pharma Ltd. (OKYO) has a current P/OCF of 0.00. The 5-year average P/OCF is -2.52. The thresholds are as follows: Strongly Undervalued below -7.67, Undervalued between -7.67 and -5.10, Fairly Valued between 0.05 and -5.10, Overvalued between 0.05 and 2.62, and Strongly Overvalued above 2.62. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-12.18
P/FCF
OKYO Pharma Ltd. (OKYO) has a current P/FCF of -12.18. The 5-year average P/FCF is -1.30. The thresholds are as follows: Strongly Undervalued below -15.52, Undervalued between -15.52 and -8.41, Fairly Valued between 5.80 and -8.41, Overvalued between 5.80 and 12.91, and Strongly Overvalued above 12.91. The current Forward P/FCF of -12.18 falls within the Undervalued range.
OKYO Pharma Ltd (OKYO) has a current Price-to-Book (P/B) ratio of -17.78. Compared to its 3-year average P/B ratio of -13.12 , the current P/B ratio is approximately 35.54% higher. Relative to its 5-year average P/B ratio of -10.52, the current P/B ratio is about 69.07% higher. OKYO Pharma Ltd (OKYO) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -15.68%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -14.64% , the current FCF yield is about -100.00% lower.
-17.78
P/B
Median3y
-13.12
Median5y
-10.52
-1.77
FCF Yield
Median3y
-15.68
Median5y
-14.64
Competitors Valuation Multiple
The average P/S ratio for OKYO's competitors is 2.83, providing a benchmark for relative valuation. OKYO Pharma Ltd Corp (OKYO) exhibits a P/S ratio of 2.74, which is -3.05% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Performance Decomposition
1Y
3Y
5Y
Market capitalization of OKYO increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of OKYO in the past 1 year is driven by Unknown.
People Also Watch
FAQ
Is OKYO Pharma Ltd (OKYO) currently overvalued or undervalued?
OKYO Pharma Ltd (OKYO) is now in the Fair zone, suggesting that its current forward PS ratio of 2.74 is considered Fairly compared with the five-year average of -5.35. The fair price of OKYO Pharma Ltd (OKYO) is between to according to relative valuation methord.
What is OKYO Pharma Ltd (OKYO) fair value?
How does OKYO's valuation metrics compare to the industry average?
What is the current P/B ratio for OKYO Pharma Ltd (OKYO) as of Nov 04 2025?
What is the current FCF Yield for OKYO Pharma Ltd (OKYO) as of Nov 04 2025?
What is the current Forward P/E ratio for OKYO Pharma Ltd (OKYO) as of Nov 04 2025?